Amgen (GB:0R0T)
LSE:0R0T

Amgen (0R0T) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0R0T Analyst Ratings

Moderate Buy
21Ratings
12 Buy
8 Hold
1 Sell
Based on 21 analysts giving stock ratings to
Amgen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0R0T Stock 12 Month Forecast

Average Price Target

$323.18
▼(-4.67% Downside)
Based on 21 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $323.18 with a high forecast of $380.00 and a low forecast of $215.00. The average price target represents a -4.67% change from the last price of $339.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"214":"$214","381":"$381","255.75":"$255.8","297.5":"$297.5","339.25":"$339.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":323.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$323.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$215.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[214,255.75,297.5,339.25,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.5,316.7692307692308,322.03846153846155,327.3076923076923,332.5769230769231,337.84615384615387,343.11538461538464,348.38461538461536,353.65384615384613,358.9230769230769,364.1923076923077,369.46153846153845,374.7307692307692,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.5,312.39846153846156,313.29692307692306,314.1953846153846,315.09384615384613,315.9923076923077,316.89076923076925,317.78923076923076,318.6876923076923,319.5861538461539,320.4846153846154,321.38307692307694,322.28153846153845,{"y":323.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.5,304.0769230769231,296.65384615384613,289.2307692307692,281.8076923076923,274.38461538461536,266.96153846153845,259.53846153846155,252.1153846153846,244.69230769230768,237.26923076923077,229.84615384615384,222.4230769230769,{"y":215,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":227.764,"date":1689897600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.699,"date":1691107200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":250.884,"date":1693526400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":260.412,"date":1696550400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":263.832,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":265.467,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.234,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":316.689,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.718,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.791,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.537,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":307.25,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":311.5,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$380.00Average Price Target$323.18Lowest Price Target$215.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Performance
Any
Any
Analyst Rating
Any
Any
Upside / Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo
$320
Buy
$320.00
(-5.60% Downside)
Reiterated
05/21/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Omnicell (NASDAQ: OMCL), Tandem Diabetes Care (NASDAQ: TNDM) and Amgen (NASDAQ: AMGN)
Truist Financial
Buy
Reiterated
05/21/24
Amgen (AMGN) Gets a Buy from Truist Financial
Mizuho Securities
$235
Hold
$235.00
(-30.68% Downside)
Reiterated
05/20/24
Maintaining Hold on Amgen: Mixed Clinical Results and Cautious Adoption of New Therapy
BMO Capital
$355
Buy
$355.00
(4.72% Upside)
Reiterated
05/19/24
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbSci (NASDAQ: ABSI) and Amgen (NASDAQ: AMGN)
Oppenheimer
$380
Buy
$380.00
(12.09% Upside)
Reiterated
05/17/24
Oppenheimer reiterates Outperform Rating on Amgen (AMGN)Oppenheimer analyst Jay Olson reiterated an Outperform rating and $380.00 price target on Amgen (NASDAQ: AMGN).

Best Analysts Covering Amgen

Which Analyst Should I Follow If I Want to Buy GB:0R0T and Sell After:
1 Month
xxx
Success Rate
14/27 ratings generated profit
52%
Average Return
-0.59%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 51.85% of your transactions generating a profit, with an average return of -0.59% per trade.
3 Months
xxx
Success Rate
20/28 ratings generated profit
71%
Average Return
+7.18%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +7.18% per trade.
1 Year
Yaron WerberTD Cowen
Success Rate
24/28 ratings generated profit
86%
Average Return
+17.99%
reiterated a buy rating 4 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +17.99% per trade.
2 Years
xxx
Success Rate
33/35 ratings generated profit
94%
Average Return
+21.45%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 94.29% of your transactions generating a profit, with an average return of +21.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0R0T Analyst Recommendation Trends

Rating
Mar 24
Apr 24
May 24
Jun 24
Jul 24
Strong Buy
0
0
0
0
0
Buy
28
29
33
32
27
Hold
13
12
17
17
19
Sell
5
5
2
2
1
Strong Sell
0
0
0
0
0
total
46
46
52
51
47
In the current month, 0R0T has received 27 Buy Ratings, 19 Hold Ratings, and 1 Sell Ratings. 0R0T average Analyst price target in the past 3 months is $323.18.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0R0T Financial Forecast

0R0T Earnings Forecast

Next quarter’s earnings estimate for 0R0T is $5.00 with a range of $4.78 to $5.43. The previous quarter’s EPS was $3.96. 0R0T beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.38% of the time in the same period. In the last calendar year 0R0T has Outperformed its overall industry.
Next quarter’s earnings estimate for 0R0T is $5.00 with a range of $4.78 to $5.43. The previous quarter’s EPS was $3.96. 0R0T beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.38% of the time in the same period. In the last calendar year 0R0T has Outperformed its overall industry.

0R0T Sales Forecast

Next quarter’s sales forecast for 0R0T is $8.34B with a range of $8.21B to $8.60B. The previous quarter’s sales results were $7.40B. 0R0T beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 45.00% of the time in the same period. In the last calendar year 0R0T has Outperformed its overall industry.
Next quarter’s sales forecast for 0R0T is $8.34B with a range of $8.21B to $8.60B. The previous quarter’s sales results were $7.40B. 0R0T beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 45.00% of the time in the same period. In the last calendar year 0R0T has Outperformed its overall industry.

0R0T Stock Forecast FAQ

What is GB:0R0T’s average 12-month price target, according to analysts?
Based on analyst ratings, Amgen’s 12-month average price target is $323.18.
    What is GB:0R0T’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for GB:0R0T, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Amgen a Buy, Sell or Hold?
        Amgen has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 8 hold ratings and 1 sell ratings.
          What is Amgen’s share price target?
          The average share price target for Amgen is $323.18. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $380.00 ,and the lowest forecast is $215.00. The average share price target represents -4.67% Decrease from the current price of $339.
            What do analysts say about Amgen?
            Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
              How can I buy shares of Amgen?
              To buy shares of GB:0R0T, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis